Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia.

PubWeight™: 0.83^‹?›

🔗 View Article (PMID 26055304)

Published in Leukemia on June 09, 2015

Authors

M S Khodadoust¹, B Luo¹^,2, B C Medeiros¹, R C Johnson², M D Ewalt², A S Schalkwyk³, C D Bangs², A M Cherry², S Arai⁴, D A Arber², J L Zehnder¹^,2, J Gotlib¹

Author Affiliations

1: Division of Hematology, Department of Medicine, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA, USA.
2: Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
3: Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
4: Division of Bone Marrow Transplantation, Department of Medicine, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA, USA.

Articles citing this ↘

SCLLTargeting FGFR1 to suppress leukemogenesis in syndromic and de novo AML in murine models. Oncotarget (2016) 0.75

Polypharmacology in Precision Oncology: Current Applications and Future Prospects. Curr Pharm Des (2016) 0.75

Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and CEP110-FGFR1 Rearrangement. Oncologist (2017) 0.75

Articles cited by this ↗

8p11 myeloproliferative syndrome: a review. Hum Pathol (2010) 1.81

PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A (2004) 1.81

The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood (2001) 1.47

Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood (2007) 1.40

Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities. Leukemia (2012) 1.34

Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL. Genes Chromosomes Cancer (2001) 1.09

t(8;22)/BCR-FGFR1 myeloproliferative disorder presenting as B-acute lymphoblastic leukemia: report of a case treated with sorafenib and review of the literature. Leuk Res (2011) 1.02

Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome. Haematologica (2012) 0.96

Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusion. Int J Oncol (2005) 0.93

Chronic myeloproliferative disorder with t(8;22)(p11;q11) can mime clonal cytogenetic evolution of authentic chronic myelogeneous leukemia. Genes Chromosomes Cancer (2008) 0.93

A case of 8p11 myeloproliferative syndrome with BCR-FGFR1 gene fusion presenting with trilineage acute leukemia/lymphoma, successfully treated by cord blood transplantation. Acta Haematol (2012) 0.89

Allogeneic Hematopoietic Stem Cell Transplantation for a BCR-FGFR1 Myeloproliferative Neoplasm Presenting as Acute Lymphoblastic Leukemia. Case Rep Hematol (2012) 0.89

Favorable outcome of allogeneic hematopoietic cell transplantation for 8p11 myeloproliferative syndrome associated with BCR-FGFR1 gene fusion. Pediatr Blood Cancer (2011) 0.86

Clinical evidence for a graft-versus-tumour effect following allogeneic HSCT for t(8;13) atypical myeloproliferative disorder. Bone Marrow Transplant (2009) 0.83